The NeurologyLive® MS Disease Spotlight page offers specific updates and coverage on the latest expert conversations and data readouts related to the treatment and management of patients with multiple sclerosis and demyelinating disorders.
April 28th 2025
Bruce Bebo, PhD, and Amit Bar-Or, MD, FRCPC, FAAN, FANA, discussed the impact of the John Dystel Prize on multiple sclerosis research and its role in shaping future clinical advancements.
Future Directions and Takeaways Regarding Anti-CD20 Therapies in MS
May 20th 2024Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, share perspectives on the future of MS care, the importance of vigilance in lab testing, and why patients may need reassurance about the potential for disease control with currently available therapies.
Open-Label Data vs Real-World Data for Anti-CD20 Therapies in Multiple Sclerosis
May 14th 2024Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, discuss the utility of real-world data, particularly when it comes to understanding subtle differences between agents from both a safety and efficacy perspective.
A Call to Action to Address Disparities in Multiple Sclerosis Care: Jaime Imitola, MD
Published: May 6th 2024 | Updated: May 6th 2024The chief of the Division of MS and Neuroimmunology at UConn Health talked about the challenges with access to care in multiple sclerosis, particularly for marginalized communities, despite significant progress made in the field over the past decades. [WATCH TIME: 4 minutes]
FDA Allows Additional Enrollment to Foralumab Expanded Access Program
May 4th 2024To date, treatment with foralumab has shown promising results in stabilizing or improving clinical measures without serious adverse effects among patients with non-active secondary progressive multiple sclerosis.
The Importance of Lifestyle Changes in Multiple Sclerosis Care
April 29th 2024Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, review the benefits of exercise and physical activity in patients with MS. They also discuss strategies for talking to patients about the positive effects of lifestyle changes.
Pregnancy and Lactation in Multiple Sclerosis
April 22nd 2024Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, review strategies for optimizing treatment of women with MS who are pregnant while minimizing risks. They also talk about evolving approaches to managing women who are breastfeeding.
Immunological Phenotypes of Multiple Sclerosis and Patient Race
April 22nd 2024Ahmed Obeidat, MD, PhD, Erin Longbrake, MD, PhD, Stephen Krieger, MD, and Riley Bove, MD, discuss differences in immunologic phenotypes across racial boundaries. They also discuss data showing that, despite these differences, response to high-efficacy agents appears to be consistent regardless of race.
Safety of Cancer Treatments in Patients With Multiple Sclerosis: Prashanth Rajarajan, MD, PhD
April 17th 2024The neurology resident at Massachusetts General Brigham talked about assessing the safety of cancer treatments in patients with multiple sclerosis using checkpoint inhibitors. [WATCH TIME: 6 minutes]
Pregnancy Outcomes of Maternal Exposure to Ocrelizumab: Riley Bove, MD
April 16th 2024The associate professor of neurology at University of California, San Francisco talked about findings from an analysis that assessed the safety of ocrelizumab when administered close to pregnancy. [WATCH TIME: 5 minutes]
Recognizing Excellence in Multiple Sclerosis Research, the Dystel Prize: Bruce Bebo, PhD
April 15th 2024The executive vice president of research at National MS Society talked about the Dystel Prize which is presented at AAN to a recognized individual who promotes further advancements in understanding and treating MS. [WATCH TIME: 3 minutes]
New Insights into BTK Inhibitors and MRI Techniques for Smoldering MS: Thomas F. Scott, MD
April 14th 2024The director of the Allegheny Multiple Sclerosis Treatment Center at Allegheny General Hospital discussed exploring the potential role of BTK inhibitors and advanced MRI techniques to address smoldering multiple sclerosis. [WATCH TIME: 10 minutes]